The nickname "Ozempic face" names something real, a face that looks thinner, looser or older after losing a lot of weight, but it isn't a medical term. Ozempic is a type 2 diabetes drug; the same molecule, semaglutide, is sold for weight as Wegovy. Neither label lists facial changes [1] [2].
What people mean by "Ozempic face"
It's shorthand for facial hollowing, looser skin and deeper folds during GLP-1 weight loss. A 2026 review of 46 published reports describes the same three features: "facial hollowing, skin laxity, and more prominent folds" [3]. The imaging studies below measure the midface, the cheek area between the eyes and the mouth, where those changes are easiest to quantify.
The review's author makes a point about the name itself: "Ozempic face" can imply a drug-specific side effect, "although similar changes occur after other forms of substantial weight loss" [3]. That's the core of the answer. The face changes because it loses fat, not because semaglutide does something special to facial tissue.
Is it a side effect of Ozempic?
Not in the label's sense: neither Ozempic's nor Wegovy's prescribing information lists facial changes. The only place either label mentions the face is swelling of the face, lips or tongue as a sign of an allergic reaction, which is a different and urgent problem [1] [2].
What the Wegovy label does say is relevant. Semaglutide "lowers body weight with greater fat mass loss than lean mass loss" [2]. Facial fat goes along with fat everywhere else. The label also lists hair loss, which it says was "associated with weight reduction": 3.3% of people on Wegovy 2.4 mg reported it, against 1% on placebo, and 5.8% at the 7.2 mg dose [2]. Ozempic's label lists hair loss among reports received after approval [1].
What causes it
The leading explanation is lost facial fat after substantial weight loss, layered on top of normal aging. The 2026 review concludes that "current evidence favors weight-loss-associated deflation superimposed on baseline anatomy and aging" [3].
A second 2026 review, from dermatologists at Mayo Clinic, looks at the tissue level. It points to three contributors: loss of the fat layer within the skin (dermal white adipose tissue), changes in the facial bones over time, and loss of muscle mass [4]. Its authors declared no competing interests. Aging does the same things slowly; large weight loss can make them visible in months.
How much facial volume changes
In one small imaging series, midface volume fell by a median 9%. That's the clearest number the research has so far, and it comes from only 20 patients [3].
| Finding | Type of evidence | Size | Source |
|---|---|---|---|
| Median 9% loss of midface volume | Serial 3D imaging | 20 patients | Yoo 2026 review [3] |
| More loss in the superficial fat layer (11%) than the deep layer (7%) | Same imaging series | 20 patients | [3] |
| About 7% midface volume loss per 22 pounds (10 kg) of body weight lost | Regression on imaging data | Imaging series | [3] |
| More reports of facial volume loss and laxity with greater percentage weight loss | Survey | 1,226 people | [3] |
| Facial deflation and older apparent age after bariatric surgery, more so in older patients and after larger losses | Post-surgery studies cited in the review | Several studies | [3] |
| A FACE-Q short-form questionnaire validated for rating these changes | Validation study | Not stated in the summary | [3] |
The review covered 46 reports published from January 2014 through August 2026.
To put the regression number in context: someone who loses 44 pounds (20 kg) would, on that estimate, lose roughly 14% of midface volume. It's an average from a small group, not a prediction for any one face.
What that could mean at the weight losses in Wegovy's trials
Wegovy's label gives the scale of loss the estimate applies to. In its main 68-week trial of adults without diabetes, people started at an average of 232.4 pounds (105.4 kg) and lost 14.9% of body weight on 2.4 mg, against 2.4% on placebo [2]. That is about 34.6 pounds (15.7 kg). On the review's estimate of about 7% per 22 pounds (10 kg), that works out to roughly 11% of midface volume, by our arithmetic.
People with type 2 diabetes, the group Ozempic is approved for, lost less in the label's trial: 9.6% on Wegovy 2.4 mg, against 3.4% on placebo [2]. Smaller losses mean smaller expected facial change, on the same estimate. Two cautions apply. The 7%-per-10-kg figure came from 20 people, and faces start from different amounts of fat, skin elasticity and age. Treat it as a rough scale, not a forecast.
Who is more likely to notice it
Larger losses and older age are the factors the research mentions most. In the survey of 1,226 people, reports of facial volume loss and laxity rose with the percentage of body weight lost [3]. After bariatric surgery, the change was most visible in older patients and after the largest losses.
Speed is a common worry, but it isn't settled. The review says the separate effect of how fast weight comes off, and the roles of menopause and hormone therapy, "remain uncertain" [3]. A slower pace may feel safer, yet no study has shown that it protects the face.
Can you prevent it?
No prevention method has been tested in a controlled trial. The review's verdict on treatments is short: "Aesthetic treatment evidence is limited and largely uncontrolled" [3]. That covers fillers, devices and skin products alike, so this page doesn't recommend any of them.
What you can do is talk with your prescriber about your goals and your pace, and mention it if facial change bothers you. The Mayo review frames care around a "health-first approach" that puts preserving tissue first [4]. Your prescriber can also check that you're keeping enough muscle, since lean-mass loss is one of the contributors.
"Ozempic teeth," "Ozempic butt" and other nicknames
These are informal terms with little research behind them. "Ozempic teeth" has the most data, and that data is mostly reassuring.
A 2026 study matched 226,485 GLP-1 users with similar people not taking the drugs. Most mouth, gum, salivary and dental conditions were not more common on GLP-1 drugs, and several were less common. The one condition with higher odds was reflux (GERD), the most frequent event at 5.36% [5]. The authors declared no conflicts of interest, and it was an observational study.
A dental review the same year adds a caution: reflux and vomiting pose "a plausible but unquantified risk for tooth erosion" [6]. It also notes reports of dry mouth and taste changes with semaglutide, and that no prospective study has yet measured a dental outcome in people on these drugs. For stomach acid and reflux, see Ozempic stomach side effects; for dry mouth, see peeing, thirst and dry mouth on Ozempic.
| Term | What it refers to | What's known | Source |
|---|---|---|---|
| Ozempic face | Hollowing and loose skin in the face | Weight-loss deflation; about 7% midface volume per 22 pounds (10 kg) in one imaging series | [3] |
| Ozempic teeth | Tooth or gum problems | No rise in most oral conditions in a large cohort; reflux more common | [5] [6] |
| Hair loss | Thinning hair | On the Wegovy label, tied to weight reduction: 3.3% vs 1% on placebo | [2] |
| Ozempic butt, feet, neck | Looser skin or less fat elsewhere | Same deflation idea; no published studies of these terms | PubMed search |
What to ask your prescriber
- How fast am I losing, and does that pace fit my goals?
- Am I keeping muscle, and should I be doing anything to protect it?
- Is hair thinning something to watch in my case?
- Is my reflux or vomiting frequent enough to mention to my dentist?
For the drug's other warnings, read Ozempic safety and side effects and Wegovy side effects.
See how the 21 brand Wegovy and Zepbound self-pay programs we score compare on monthly cost and care.